Mark Hodgkinson

Mark Hodgkinson has a diverse work experience in the pharmaceutical industry. Mark started their career at Roche Pharmaceuticals in 2008, where they gained experience in regulatory affairs including CTA applications, amendments, and post-licensing activities. Mark then worked at AstraZeneca as a Regulatory Affairs Manager, where they focused on clinical trial submissions and lifecycle management of registered products. Mark joined Teva Pharmaceuticals in 2014 as a Senior Manager, leading regulatory strategy for oncology and pain products in the European market. Since 2017, they have been working at Eisai EMEA, starting as a Senior Manager and progressing to Associate Director and currently Director. In their roles at Eisai EMEA, Mark's responsibilities have included global regulatory lead for Alzheimer's Disease compounds, providing regulatory strategy for accelerated programs, overseeing global filings, leading scientific advice meetings with regulatory authorities, and coordinating phase 3 start-ups and maintenance. Overall, Mark has demonstrated expertise in regulatory strategy, project management, and stakeholder engagement throughout their career.

Mark Hodgkinson completed their undergraduate education at the University of Leeds from 2002 to 2005, earning a Bachelor of Science degree in Pharmacology. Mark later pursued a Master's degree in Toxicology at the University of Birmingham from 2007 to 2008.